middle.news
Actinogen identifies older-patient signal in mixed XanaMIA Alzheimer’s trial
8:32am on Thursday 19th of November, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Actinogen identifies older-patient signal in mixed XanaMIA Alzheimer’s trial
8:32am on Thursday 19th of November, 2026 AEDT
Key Points
Non-significant 0.10-point CDR-SB benefit across the full trial at 36 weeks
40% of participants over 75 had no disease progression versus 22% on placebo
Older subgroup showed estimated 30% disease slowing, but this measure was not statistically significant
No serious adverse events were attributed to Xanamem over 36 weeks
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE